(Q37016110)

17 August 2017

1 reference

title

A review of the efficacy and tolerability of agomelatine in the treatment of major depression (English)

1 reference

17 August 2017

Anita Ghosh

1

1 reference

17 August 2017

Jonathan S E Hellewell

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

published in

1 reference

17 August 2017

volume

16

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

1999-2004

1 reference

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Placebo-controlled trial of agomelatine in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

The epidemiology of panic disorder and agoraphobia in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1999

10.1517/13543784.16.12.1999

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference